Appendix A
References

Adams, W. G., K. A. Deaver, S. L. Cochi, B. D. Plikaytis, E. R. Zell, C. V. Broome, and J. D. Wenger. 1993. Decline of childhood haemophilus influenzae type b (hib) disease in the hib vaccine era. Journal of the American Medical Association 269(2):221-226.

Armstrong, J. 1982. The value of formal planning for strategic decisions: Review of empirical research. Strategic Management Journal 3(3):197-211.

Braun, M. M., G. T. Mootrey, M. E. Salive, R. T. Chen, S. S. Ellenberg, and V. W. Group. 2000. Infant immunization with acellular pertussis vaccines in the United States: Assessment of the first two years’ data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 106(4).

CDC (Centers for Disease Control and Prevention). 2000 (May 19). Poliomyelitis Prevention in the United States. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Morality Weekly Report 49(RR05):1-22.

CDC. 2001. Vaccines and preventable diseases: Decreased availability of pneumococcal conjugate vaccine (PCV-7). http://www.cdc.gov/vaccines/vagen/shortages/past/pneumo-2001.htm (accessed June 5, 2008).

CDC. 2006 (December 15). Immunization information systems progress—United States, 2005. Morbidity and Morality Weekly Report 55(49):1327-1329.

CDC. 2007a. What would happen if we stopped vaccinations? http://www.cdc.gov/vaccines/vacgen/whatifstop.htm (accessed April 29, 2008).

CDC. 2007b (August 31). National, state, and local area vaccination coverage among children aged 19—35 months—United States, 2006. Morbidity and Morality Weekly Report 56(34):880-885.

CDC 2008. Current vaccine shortages and delays. http://www.cdc.gov/vaccines/vacgen/shortages/default.htm#why (accessed June 5, 2008).

Clements, C. J., and S. Ratzan. 2003. Misled and confused? Telling the public about MMR vaccine safety. Journal of Medical Ethics 29:22-26.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 19
Appendix A References Adams, W. G., K. A. Deaver, S. L. Cochi, B. D. Plikaytis, E. R. Zell, C. V. Broome, and J. D. Wenger. 1993. Decline of childhood haemophilus influenzae type b (hib) disease in the hib vaccine era. Journal of the American Medical Association 269(2):221-226. Armstrong, J. 1982. The value of formal planning for strategic decisions: Review of empirical research. Strategic Management Journal 3(3):197-211. Braun, M. M., G. T. Mootrey, M. E. Salive, R. T. Chen, S. S. Ellenberg, and V. W. Group. 2000. Infant immunization with acellular pertussis vaccines in the United States: Assessment of the first two years’ data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 106(4). CDC (Centers for Disease Control and Prevention). 2000 (May 19). Poliomyelitis Prevention in the United States. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Morality Weekly Report 49(RR05):1-22. CDC. 2001. Vaccines and preventable diseases: Decreased availability of pneumococcal conjugate vaccine (PCV-7). http://www.cdc.gov/vaccines/vac- gen/shortages/past/pneumo-2001.htm (accessed June 5, 2008). CDC. 2006 (December 15). Immunization information systems progress—United States, 2005. Morbidity and Morality Weekly Report 55(49):1327-1329. CDC. 2007a. What would happen if we stopped vaccinations? http://www.cdc.gov/vaccines/vac- gen/whatifstop.htm (accessed April 29, 2008). CDC. 2007b (August 31). National, state, and local area vaccination coverage among children aged 19—35 months—United States, 2006. Morbidity and Morality Weekly Report 56(34):880-885. CDC 2008. Current vaccine shortages and delays. http://www.cdc.gov/vaccines/vac- gen/shortages/default.htm#why (accessed June 5, 2008). Clements, C. J., and S. Ratzan. 2003. Misled and confused? Telling the public about MMR vaccine safety. Journal of Medical Ethics 29:22-26. 19

OCR for page 19
20 INITIAL GUIDANCE Clements, C., G. Evans, S. Dittman, and A. Reeler. 1999. Vaccine safety concerns everyone. Vaccine October 29(17 Suppl 3):S90-S94. CMS (Centers for Medicare and Medicaid Services). 2006. Medicaid managed care enrollment report. http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/Downloads/mmcer06.pdf (accessed April 21, 2008). Colgrove, J., and R. Bayer. 2005. Could it happen here? Vaccine risk controversies and the specter of derailment. Health Affairs 24(3):729-739. Cutts, F. T., S. M. A. Zaman, G. Enwere, S. Jaffar, O. S. Levine, J. B. Okoko, C. Oluwalana, A. Vaughan, S. K. Obaro, A. Leach, K. P. McAdam, E. Biney, M. Saaka, U. Onwuchekwa, F. Yallop, N. F. Pierce, B. M. Greenwood, and R. A. Adegbola. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: Randomised, double-blind, placebo-controlled trial. The Lancet 365(9465):1139-1146. IOM (Institute of Medicine). 2008. Transcript of meeting one of the Committee on the Review of Priorities in the National Vaccine Plan. Washington, DC. IOM Staff. 2008. IOM staff notes: Major themes from conversations with key individuals knowledgeable about the process of preparing the 1994 National Vaccine Plan. Washington, DC. Iskander, J. 2007. Current CDC vaccine safety activities. Presentation at Vaccine Safety Evaluation: Post Marketing Surveillance Conference. Bethesda, MD. Kaplan, R. S., and D. P. Norton. 1992. The balanced scorecard: Measures that drive performance. Harvard Business Review 70(1):71-79. The Keystone Center. 2005. Citizen voices on pandemic flu choices: A report of the public engagement pilot project on pandemic influenza. http://www.keystone.org/spp/documents/FINALREPORT_PEPPPI_DEC_2005. pdf (accessed June 3, 2008). Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, N. Pierce, and the Vaccine Trialists Group. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine 349(14):1341-1348. Lee, G. M., J. M. Santoli, and C. Hannan. 2007. Gaps in vaccine financing for underinsured children in the United States. Journal of the American Medical Association 298(6):638- 643. Milstien, J. B., M. Kaddar, and M. P. Kieny. 2006. The impact of globalization on vaccine development and availability. Health Affairs 25(4):1061-1069. NIAID (National Institute of Allergy and Infectious Diseases). 1998. Task force on safer childhood vaccines: Final report and recommendations. Bethesda, MD: National Institues of Health. NVAC (National Vaccine Advisory Committee). 2004. Public participation working group meeting on models for enhancing public involvement in vaccine decision-making meeting summary. http://www.hhs.gov/nvpo/public_participation/NVAC_Public_Participcompleteminutes.h tml (accessed May 22, 2008). NVPO (National Vaccine Program Office). 1994. Disease prevention through vaccine development and immunization: The U.S. National Vaccine Plan—1994. Washington, DC: Department of Health and Human Services. NVPO. 1997. NVPO Interagency group workshop agenda book. St. Michaels, MD: NVPO. Orenstein, W. A. 2008. Draft priorities of the national vaccine plan. Presentation at Meeting One of the Committee on Review of Priorities in the National Vaccine Plan. Washington, DC.

OCR for page 19
APPENDIX A 21 Poland, G. A., and R. M. Jacobson. 2001. Understanding those who do not understand: A brief review of the anti-vaccine movement. Vaccine 19:2440-2445. Stewart, A., S. Rosenbaum, M. Cox, and A. Lee. 2003. Medicaid coverage of immunizations for non-institutionalized adults. Washington, DC: The George Washington University. http://www.gwumc.edu/sphhs/departments/healthpolicy/chsrp/downloads/Medicaid_Imm unization_Study.pdf (accessed June 5, 2008). Wattigney, W. A., G. T. Mootrey, M. M. Braun, and R. T. Chen. 2001. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: Impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 107(83). Whitman, B. 2008. Clearing up confusion over Medicare coverage for vaccines. ACP Internist March 2008:8. http://www.acponline.org/clinical_information/journals_publications/acp_internist/mar08 /nine.htm (accessed May 15, 2008). Wysocki, B., and S. Lueck. 2006. Margin of safety: Just-in-time inventories make U.S. vulnerable in a pandemic. Wall Street Journal, January 12, 2006. Zhou, F., J. Santoli, M. L. Messonnier, H. R. Yusuf, A. Shefer, S. Y. Chu, L. Rodewald, and R. Harpaz. 2005. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Archives of Pediatric & Adolescent Medicine 159(12):1136-1144.